Home » Cancer Drug Enfortumab Vedotin Receives FDA Designation
Cancer Drug Enfortumab Vedotin Receives FDA Designation
March 27, 2018
The FDA granted a breakthrough therapy designation for Astellas Pharma and Seattle Genetics’ antibody-drug conjugate, enfortumab vedotin. The drug is intended for patients with locally advanced or metastatic urothelial cancer who were previously being treated with checkpoint inhibitors.
The treatment targets Nectin-4, a cell adhesion molecule that Astellas determined to be expressed on many solid tumors. The technology, developed by Seattle Genetics, uses the targeting ability of antibodies to apply cell-killing agents to cancer cells.
The drug’s effectiveness is also being evaluated in other tumors, such as ovarian and non-small cell lung carcinoma.
Upcoming Events
-
21Oct